Events, Appointments, Approvals, Recommendations, and Agreements - Research Report on Elan, Alkermes, Hospira, pSivida, and

 Events, Appointments, Approvals, Recommendations, and Agreements - Research
           Report on Elan, Alkermes, Hospira, pSivida, and Kindred

PR Newswire

NEW YORK, October 4, 2013

NEW YORK, October 4, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Elan
Corporation, plc (NYSE: ELN), Alkermes plc (NASDAQ: ALKS), Hospira Inc. (NYSE:
HSP), pSivida Corp. (NASDAQ: PSDV), and Kindred Healthcare Inc. (NYSE: KND).
Today's readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Elan Corporation, plc Research Report

On September 30, 2013, Elan Corporation plc (Elan) announced that it has
scheduled shareholder meetings for Monday, November 18, 2013 in connection
with Perrigo Company's (Perrigo) proposed acquisition of Elan. According to
the Company, the Company will host two special meetings of Elan shareholders
on November 18, 2013 at The DoubleTree by Hilton Hotel Dublin, Burlington
Road, Upper Leeson Street, Dublin 4, Ireland. Elan reported that the first
meeting, which is convened by order of the Irish High Court, will be held at
10:00 a.m. (Irish time), and will be followed by an extraordinary general
meeting of Elan shareholders. The Company also reported that the holders of
ordinary shares as at 5:00 p.m. (Irish time) on November 16, 2013 will be
entitled to attend and vote at the special meetings. Elan stated that holders
and beneficial owners of American Depositary Shares (ADSs) as at 5:00 p.m.
(New York City time) on October 11, 2013 (ADS Voting Record Date) will have
the opportunity to instruct the ADS Depositary to vote the shares represented
by ADSs that they hold as of the ADS Voting Record Date. The Company expects
to mail the Scheme Circular and meeting materials to its shareholders by no
later than October 17, 2013. The Full Research Report on Elan Corporation, plc
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/e996_ELN]

--

Alkermes plc Research Report

On September 30, 2013, Alkermes plc (Alkermes) announced the appointments to
its senior management team. Alkermes appointed Srdjan (Serge) Stankovic, M.D.,
MSPH, as Senior Vice President of Clinical Development and Medical Affairs,
and Peter Norman as Vice President of Government Affairs and Policy. Richard
Pops, CEO of Alkermes, commented, "As our portfolio of new medicines expands,
we are responding by strengthening our capabilities in two areas critical for
our future: global clinical development and government affairs." The Full
Research Report on Alkermes plc - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/e2f3_ALKS]

--

Hospira Inc. Research Report

On September 10, 2013, Hospira Inc. (Hospira) announced that the European
Commission (EC)approved Inflectra (infliximab), Europe's first biosimilar
monoclonal antibody (mAb) therapy. According to Hospira, Inflectra has been
approved for the treatment of inflammatory conditions including rheumatoid
arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative
colitis (UC), psoriatic arthritis (PsA), and psoriasis. Dr. Stan Bukofzer,
Corporate Vice President and Chief Medical Officer, Hospira, stated, "The
rigorous scientific review and approval process by the EMA and EC confirms
that Inflectra has demonstrated similar quality, efficacy and safety to
Remicade. For over a decade biologic medicines have been pivotal in treating a
range of inflammatory conditions, so the granting of marketing authorisation
in Europe is a major milestone for Inflectra, and for the future of biologic
therapy." The Full Research Report on Hospira Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.AnalystsCorner.com/r/full_research_report/1f43_HSP]

--

pSivida Corp. Research Report

On September 30, 2013, pSivida Corp. (pSivida) announced that the United
Kingdom's National Institute for Health and Care Excellence (NICE) issued
final draft guidance recommending ILUVIEN as an option for the treatment of
chronic diabetic macular edema (DME) that is insufficiently responsive to
available therapies in pseudophakic eyes - those that have already undergone
cataract surgery. pSivida reported that the recommendation reverses the final
draft guidance previously issued by NICE with respect to this subgroup of
chronic DME patients. Dr. Paul Ashton, President and CEO of pSivida said, "We
are encouraged that Alimera plans to continue to work with NICE in an effort
to broaden access to ILUVIEN to include all chronic DME patients who could
benefit from the treatment." The Full Research Report on pSivida Corp. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/d4eb_PSDV]

--

Kindred Healthcare Inc. Research Report

On October 1, 2013, Kindred Healthcare Inc. (Kindred) announced it has entered
into agreements to renew early its leases with Ventas, Inc. (Ventas) for 22
transitional care (TC) hospitals (certified as long-term acute care hospitals)
and 26 nursing and rehabilitation centers (collectively, the Renewal
Facilities). Kindred reported that the current lease term for the Renewal
Facilities was scheduled to expire in April 2015. According to the Company,
the current aggregate annual rent for the Renewal Facilities approximates $79
million. Paul J. Diaz, CEO of Kindred, remarked, "We are pleased to have
negotiated a mutually beneficial transaction with Ventas that accelerates our
strategic repositioning plan in 2014 and paves the way for us to grow and
advance our Integrated Care Market development plans. This transaction will be
slightly accretive to Kindred's earnings in 2014 and will allow us to retain
all of our TC hospitals that are up for renewal, along with several high
quality nursing and rehabilitation centers. These transactions reflect another
step in our maturing and improving relationship with Ventas and allow both
companies to focus on the future and the creation of value for our patients
and shareholders." The Full Research Report on Kindred Healthcare Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/ab58_KND]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.